Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Otago Medical School staff profiles

Associate Professor Catherine Stedman

PositionClinical Associate Professor
DepartmentDepartment of Medicine (UOC)
Research summaryLiver disease

Research

Dr Stedman's field of research is liver disease and pharmacology, focusing on hepatitis C and autoimmune liver diseases. Her published papers in hepatitis C epidemiology have influenced global understanding of chronic hepatitis C epidemiology including government and Ministry of Health understanding and approach to hepatitis C treatment strategies.

Publications

Tharayil, V. S., Chalmers-Watson, T., Cole, D., & Stedman, C. (2019). Oesophageal tuberculosis: A rare cause of dysphagia. Annals of Clinical Case Reports, 4, 1597. [Case Study].

Gane, E. J., Stedman, C. A., Schwabe, C., Vijgen, L., Chanda, S., Kakuda, T. N., … McClure, M. W. (2018). Short duration AL-335, odalasvir, with or without simeprevir, in patients with HCV GT1 or 3 infection without cirrhosis. Hepatology, 68(6), 2145-2157. doi: 10.1002/hep.30126

Grebely, J., Conway, B., Cunningham, E. B., Fraser, C., Moriggia, A., Gane, E., Stedman, C., … on behalf of the D3FEAT Study Group. (2018). Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. International Journal of Drug Policy, 62, 94-103. doi: 10.1016/j.drugpo.2018.10.004

Meijer, B., van Everdingen, C. K., Ramsoekh, D., Stedman, C., Frampton, C. M. A., Mulder, C. J. J., … Gearry, R. B. (2018). Transient elastography to assess liver stiffness in patients with inflammatory bowel disease. Digestive & Liver Disease, 50(1), 48-53. doi: 10.1016/j.dld.2017.09.128

Polaris Observatory Collaborators, including Stedman, C. (2018). Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: A modelling study. Lancet Gastroenterology & Hepatology. Advance online publication. doi: 10.1016/S2468-1253(18)30056-6

Chapter in Book - Research

Stedman, C. A. M., Downes, M., & Liddle, C. (2010). Signaling pathways in liver disease: PXR and CAR. In J.-F. Dufour & P.-A. Clavien (Eds.), Signaling pathways in liver disease. (2nd ed.) (pp. 333-343). Berlin: Springer. doi: 10.1007/978-3-642-00150-5_22

Liddle, C., & Stedman, C. A. M. (2007). Hepatic metabolism of drugs. In J. Rodes, J.-P. Benhamou, A. Blei, J. Reichen & M. Rizzetto (Eds.), Textbook of hepatology: From basic science to clinical practice. (3rd ed.) (pp. 241-249). Malden, MA: Blackwell.

^ Top of page

Journal - Research Article

Gane, E. J., Stedman, C. A., Schwabe, C., Vijgen, L., Chanda, S., Kakuda, T. N., … McClure, M. W. (2018). Short duration AL-335, odalasvir, with or without simeprevir, in patients with HCV GT1 or 3 infection without cirrhosis. Hepatology, 68(6), 2145-2157. doi: 10.1002/hep.30126

Polaris Observatory Collaborators, including Stedman, C. (2018). Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: A modelling study. Lancet Gastroenterology & Hepatology. Advance online publication. doi: 10.1016/S2468-1253(18)30056-6

Meijer, B., van Everdingen, C. K., Ramsoekh, D., Stedman, C., Frampton, C. M. A., Mulder, C. J. J., … Gearry, R. B. (2018). Transient elastography to assess liver stiffness in patients with inflammatory bowel disease. Digestive & Liver Disease, 50(1), 48-53. doi: 10.1016/j.dld.2017.09.128

Grebely, J., Conway, B., Cunningham, E. B., Fraser, C., Moriggia, A., Gane, E., Stedman, C., … on behalf of the D3FEAT Study Group. (2018). Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. International Journal of Drug Policy, 62, 94-103. doi: 10.1016/j.drugpo.2018.10.004

Zeuzem, S., Foster, G. R., Wang, S., Asatryan, A., Gane, E., Feld, J. J., … Stedman, C. A., … Mensa, F. J. (2018). Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. New England Journal of Medicine, 378(4), 354-369. doi: 10.1056/NEJMoa1702417

Gane, E. J., Metivier, S., Nahass, R., Ryan, M., Stedman, C. A., Svarovskaia, E. S., … Lawitz, E. (2017). The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatment. Hepatology Communications, 1(6), 538-549. doi: 10.1002/hep4.1060

Gane, E. J., Shiffman, M. L., Etzkorn, K., Morelli, G., Stedman, C. A. M., Davis, M. N., … and the GS-US-342-1553 Investigators. (2017). Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen. Hepatology, 66(4), 1083-1089. doi: 10.1002/hep.29256

Gane, E., Stedman, C., Dole, K., Chen, J., Meyers, C. D., Wiedmann, B., … Colvin, R. A. (2017). A diacylglycerol transferase 1 inhibitor is a potent hepatitis C antiviral in vitro but not in patients in a randomized clinical trial. ACS Infectious Diseases, 3(2), 144-151. doi: 10.1021/acsinfecdis.6b00138

The Polaris Observatory HCV Collaborators, including Brunton, C. R., & Stedman, C. (2017). Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study. Lancet Gastroenterology & Hepatology, 2(3), 161-176. doi: 10.1016/S2468-1253(16)30181-9

Gane, E. J., Hyland, R. H., Yang, Y., Svarovskaia, E., Stamm, L. M., Brainard, D. M., … Stedman, C. A. M. (2017). Efficacy of ledipasvir plus sofosbuvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2 infection. Gastroenterology, 152(6), 1366-1371. doi: 10.1053/j.gastro.2017.01.017

Jacobson, I. M., Lawitz, E., Gane, E. J., Willems, B. E., Ruane, P. J., Nahass, R. G., … Stedman, C. A. M., … Foster, G. R. (2017). Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir In patients with chronic HCV infection: 2 phase 3 randomized trials. Gastroenterology, 153(1), 113-122. doi: 10.1053/j.gastro.2017.03.047

Gane, E. J., Schwabe, C., Hyland, R. H., Yang, Y., Svarovskaia, E., Stamm, L. M., … Stedman, C. A. (2016). Efficacy of the combination of sofosbuvir, velpatasvir, and the NS3/4A protease inhibitor GS-9857 in treatment-naïve or previously treated patients with HCV genotype 1 or 3 infections. Gastroenterology, 151(3), 448-456. doi: 10.1053/j.gastro.2016.05.021

Stedman, C. A. M., Hyland, R. H., Ding, X., Pang, P. S., McHutchison, J. G., & Gane, E. J. (2016). Once daily ledipasvir/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection. Haemophilia, 22(2), 214. doi: 10.1111/hae.12791

Gane, E. J., Rouzier, R., Hassanein, T., Stedman, C. A., Mazur, W., Kupcova, V., … Thommes, J. (2016). Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis. Hepatology International, 10(3), 478-487. doi: 10.1007/s12072-015-9699-9

Gane, E. J., Kowdley, K. V., Pound, D., Stedman, C. A. M., Davis, M., Etzkorn, K., … Nguyen, M. H. (2016). Efficacy of sofosbuvir, velpatasvir, and GS-9857 in patients with hepatitis C virus genotype 2, 3, 4, or 6 infections in an open-label, phase 2 trial. Gastroenterology, 151(5), 902-909. doi: 10.1053/j.gastro.2016.07.038

Naggie, S., Cooper, C., Saag, M., Workowski, K., Ruane, P., Towner, W. J., … Stedman, C. A. M., … for the ION-4 Investigators. (2015). Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. New England Journal of Medicine, 373(8), 705-713. doi: 10.1056/NEJMoa1501315

Foster, G. R., Afdhal, N., Roberts, S. K., Bräu, N., Gane, E. J., Pianko, S., … Stedman, C. A. M., … Sulkowski, M. (2015). Sofosbuvir and Velpatasvir for HCV genotype 2 and 3 infection. New England Journal of Medicine, 373(27), 2608-2617. doi: 10.1056/NEJMoa1512612

Pianko, S., Flamm, S. L., Shiffman, M. L., Kumar, S., Strasser, S. I., Dore, G. J., … Stedman, C. A. M., … Roberts, S. K. (2015). Sofosbuvir plus velpatasvir combination therapy for treatment: Experienced patients with genotype 1 or 3 hepatitis c virus infection: A randomized trial. Annals of Internal Medicine, 163(11), 809-817. doi: 10.7326/M15-1014

Gane, E., Kershenobich, D., Seguin-Devaux, C., Kristiansen, P., Aho, I., Dalgard, O., … Brunton, C. R., … Stedman, C., … Estes, C. (2015). Strategies to manage hepatitis C virus (HCV) infection disease burden: Volume 2. Journal of Viral Hepatitis, 22(Suppl. 1), 46-73. doi: 10.1111/jvh.12352

Hatzakis, A., Chulanov, V., Gadano, A. C., Bergin, C., Ben-Ari, Z., Mossong, J., … Brunton, C. R., … Stedman, C., … Razavi, H. (2015). The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm: Volume 2. Journal of Viral Hepatitis, 22(Suppl. 1), 26-45. doi: 10.1111/jvh.12351

Gane, E. J., Hyland, R. H., An, D., Svarovskaia, E., Pang, P. S., Brainard, D., & Stedman, C. A. (2015). Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology, 149, 1454-1461. doi: 10.1053/j.gastro.2015.07.063

Saraswat, V., Norris, S., de Kneft, R. J., Sanchez Avila, J. F., Sonderup, M., Zuckerman, E., … Stedman, C., … Brunton, C. R., … Gower, E. (2015). Historical epidemiology of hepatitis C virus (HCV) in select countries: Volume 2. Journal of Viral Hepatitis, 22(Suppl. 1), 6-25. doi: 10.1111/jvh.12350

Stedman, C. (2014). Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: A review of its clinical potential. Therapeutic Advances in Gastroenterology, 7(3), 131-140. doi: 10.1177/1756283x13515825

Gane, E., Stedman, C., Brunton, C., Radke, S., Henderson, C., Estes, C., & Razavi, H. (2014). Impact of improved treatment on disease burden of chronic hepatitis C in New Zealand. New Zealand Medical Journal, 127(1407). Retrieved from http://www.nzma.org.nz/journal

Gane, E. J., Stedman, C. A., Hyland, R. H., Ding, X., Svarovskaia, E., Subramanian, G. M., … Pang, P. S. (2014). Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology, 146(3), 736-743. doi: 10.1053/j.gastro.2013.11.007

Gane, E. J., Stedman, C. A., Hyland, R. H., Ding, X., Svarovskaia, E., Symonds, W. T., … Berrey, M. M. (2013). Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. New England Journal of Medicine, 368(1), 34-44. doi: 10.1056/NEJMoa1208953

Ngu, J. H., Wallace, M. C., Merriman, T. R., Gearry, R. B., Stedman, C. A. M., & Roberts, R. L. (2013). Association of the HLA locus and TNF with type I autoimmune hepatitis susceptibility in New Zealand Caucasians. SpringerPlus, 2(1), 355. doi: 10.1186/2193-1801-2-355

Ngu, J. H., Gearry, R. B., Frampton, C. M., & Stedman, C. A. M. (2013). Predictors of poor outcome in patients with autoimmune hepatitis: A population-based study. Hepatology, 57(6), 2399-2406. doi: 10.1002/hep.26290

Nishimura, T., Hu, Y., Wu, M., Pham, E., Suemizu, H., Elazar, M., … Stedman, C., … Peltz, G. (2013). Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interactions. Journal of Pharmacology & Experimental Therapeutics, 344(2), 388-396. doi: 10.1124/jpet.112.198697

Ngu, J. H., Gearry, R. B., Frampton, C. M., & Stedman, C. A. M. (2013). Autoimmune hepatitis: The role of environmental risk factors: A population-based study. Hepatology International, 7(3), 869-875. doi: 10.1007/s12072-013-9448-x

Ngu, J. H., Gearry, R. B., Wright, A. J., & Stedman, C. A. M. (2012). Low incidence and prevalence of primary biliary cirrhosis in Canterbury, New Zealand: A population-based study. Hepatology International, 6(4), 796-800. doi: 10.1007/s12072-011-9329-0

Chu, T. W., Kulkarni, R., Gane, E. J., Roberts, S. K., Stedman, C., Angus, P. W., … Shulman, N. S. (2012). Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology, 142(4), 790-795. doi: 10.1053/j.gastro.2011.12.057

Ngu, J. H., Gearry, R. B., Frampton, C. M., & Stedman, C. A. M. (2012). Mortality and the risk of malignancy in autoimmune liver diseases: A population-based study in Canterbury, New Zealand. Hepatology, 55(2), 522-529. doi: 10.1002/hep.24743

Gardiner, S. J., Gearry, R. B., Burt, M. J., Chalmers-Watson, T., Chapman, B. A., Ross, A. G., Stedman, C. A. M., … Barclay, M. L. (2011). Allopurinol might improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio. Journal of Gastroenterology & Hepatology, 26(1), 49-54. doi: 10.1111/j.1440-1746.2010.06489.x

Gane, E. J., Rouzier, R., Stedman, C., Wiercinska-Drapalo, A., Horban, A., Chang, L., … Tran, J. Q. (2011). Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients. Journal of Hepatology, 55, 972-979.

Ngu, J. H., Gearry, R. B., Wright, A. J., & Stedman, C. A. M. (2011). Inflammatory bowel disease is associated with poor outcomes of patients with primary sclerosing cholangitis. Clinical Gastroenterology & Hepatology, 9(12), 1092-1097. doi: 10.1016/j.cgh.2011.08.027

Ngu, J. H., Bechly, K., Chapman, B. A., Burt, M. J., Barclay, M. L., Gearry, R. B., & Stedman, C. A. M. (2010). Population-based epidemiology study of autoimmune hepatitis: A disease of older women? Journal of Gastroenterology & Hepatology, 25(10), 1681-1686. doi: 10.1111/j.1440-1746.2010.06384.x

Gane, E. J., Roberts, S. K., Stedman, C. A. M., Angus, P. W., Ritchie, B., Elston, R., … Smith, P. F. (2010). Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): A randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet, 376(9751), 1467-1475. doi: 10.1016/s0140-6736(10)61384-0

Jonker, J. W., Stedman, C. A. M., Liddle, C., & Downes, M. (2009). Hepatobiliary ABC transporters: Physiology, regulation and implications for disease. Frontiers in Bioscience, 14, 4904-4920. doi: 10.2741/3576

Stedman, C., Liddle, C., Coulter, S., Sonoda, J., Alvarez, J. G., Evans, R. M., & Downes, M. (2006). Benefit of farnesoid X receptor inhibition in obstructive cholestasis. PNAS, 103(30), 11323-11328.

Stedman, C. A. M., Liddle, C., Coulter, S. A., Sonoda, J., Alvarez, J. G. A., Moore, D. D., … Downes, M. (2005). Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. PNAS, 102(6), 2063-2068.

Stedman, C., Robertson, G., Coulter, S., & Liddle, C. (2004). Feed-forward regulation of bile acid detoxification by CYP3A4. Journal of Biological Chemistry, 279(12), 11336-11343.

Stedman, C. (2002). Herbal hepatotoxicity. Seminars in Liver Disease, 22(2), 195-206.

Stedman, C. A. M., Begg, E. J., Kennedy, M. A., Roberts, R., & Wilkinson, T. J. (2002). Cytochrome P450 2D6 genotype does not predict SSRI (fluoxetine or paroxetine) induced hyponatraemia. Human Psychopharmacology, 17(4), 187-190.

^ Top of page

Journal - Research Other

Tharayil, V. S., Chalmers-Watson, T., Cole, D., & Stedman, C. (2019). Oesophageal tuberculosis: A rare cause of dysphagia. Annals of Clinical Case Reports, 4, 1597. [Case Study].

Wade, A. J., Doyle, J. S., Gane, E., Stedman, C., Draper, B., Iser, D., … Hellard, M. E. (2018). Community-based provision of direct-acting antiviral therapy for hepatitis C: Study protocol and challenges of a randomized controlled trial. Trials, 19, 383. doi: 10.1186/s13063-018-2768-3

Ngu, J. H., Gearry, R. B., & Stedman, C. A. M. (2017). Autoimmune hepatitis in the East and the West. Inflammatory Intestinal Diseases, 1(4), 147-149. doi: 10.1159/000455177

Stedman, C. A. M. (2013). Current prospects for interferon-free treatment of hepatitis C in 2012. Journal of Gastroenterology & Hepatology, 28(1), 38-45. doi: 10.1111/jgh.12028

Ngu, J. H., Gearry, R. B., & Stedman, C. A. M. (2012). Has primary sclerosing cholangitis associated with Crohn's disease a better outcome? Journal of Crohn's & Colitis, 6(9), 956. doi: 10.1016/j.crohns.2012.05.013

More publications...